Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.50 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5321979 | 0.84 | KIF11 (0.53) | KIF11 | |
| SCHEMBL5924700 | 0.83 | GRM2 (0.61) | GRM2GRM3ALPIPKMPTGS1 | |
| SCHEMBL5325189 | 0.83 | GRM2 (0.61) | GRM2GRM3ALPIPKMPTGS1 | |
| SCHEMBL18886173 | 0.83 | GRM2 (0.61) | GRM2GRM3ALPIPKMPTGS1 | |
| SCHEMBL6255681 | 0.83 | GRM2 (0.61) | GRM2GRM3ALPIPKMPTGS1 | |
| SCHEMBL5924823 | 0.83 | GRM2 (0.61) | GRM2GRM3ALPIPKMPTGS1 | |
| SCHEMBL27665699 | 0.83 | KMT2A (0.51) | KIF11PTGS1TAAR1LTA4HRIPK1 | |
| SCHEMBL5323354 | 0.82 | UGT2B7 (0.47) | KIF11 | |
| SCHEMBL27254858 | 0.82 | PMP22 (0.50) | KIF11GRM2GRM3ALPIPKM | |
| Hydrochloric Acid SCHEMBL10792123 | 0.81 | GRM2 (0.59) | GRM2GRM3ALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| CN-113967258-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-25 | — | — | CN | disclosed |
| CN-113956325-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-21 | — | — | CN | disclosed |
| CN-113786495-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2021-12-14 | — | — | CN | disclosed |
| CN-106573073-B | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2021-09-28 | — | — | CN | disclosed |
| CN-106573073-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2017-04-19 | — | — | CN | disclosed |
| CN-101766546-B | Association of monosaccharides and C-glycoside derivatives and its use in cosmetics | OREAL | 2013-06-19 | — | — | CN | disclosed |
| CN-101766546-A | Association of monosaccharides and C-glycoside derivatives and its use in cosmetics | OREAL | 2010-07-07 | — | — | CN | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| US-4808713-A | Anthypertensive pyridazo [1,2-a][1,2]diazepines | HOFFMAN-LA ROCHE INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4772701-A | Pyridazo[1,2]pyridazines and pyrazolo[1,2]pyridazines as antihypertensives | HOFFMANN-LA ROCHE INC. (US) | 1988-09-20 | — | — | US | disclosed |
| US-4658024-A | Pyrazolo [1,2-a][1,2]-diazepines useful as antihypertensives | HOFFMANN-LA ROCHE INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4512924-A | HYPOTENSIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | KIF11 1678/4885GRM2 4412/4885GRM3 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.